MSC Completed the 1st Rega Series Pacemaker Implantation in Chifeng

Inner Mongolia, China, 15 July - The first implantation of Rega series pacemakers developed by MicroPort® Sorin CRM (Shanghai) Co., Ltd. (MSC) has been completed in Chifeng region, Inner Mongolia. This also marked the first implantation of domestically made pacemakers in Chifeng. The team at the Second Department of Cardiology at No. 2 Hospital of Chifeng successfully implanted the Rega series pacemakers into two elderly patients, allowing them to resume a healthy life.

The two patients suffered from atrial fibrillation combined with intermittent third-degree atrioventricular block, as well as sinus node syndrome and sinus bradycardia respectively. After comprehensive consultation of the patients’ medical history, the expert team led by Director Yueling Sun determined that the two patients should be treated with pacemaker implantation.

Due to the patients’ age and the potentially higher risk of surgery, the cardiology team selected the domestically made Rega series single-chamber pacemaker and dual-chamber pacemaker respectively for the two patients. The volume of MSC’s dual-chamber pacemaker is only 8 cubic centimeters, and the volume of the single-chamber pacemaker is only 7.5 cubic centimeters, which requires small surgical incisions and reduces the risk of postoperative infection. After thorough preoperative preparations, Director Sun's team successfully completed the surgeries. All pacing parameters and patient conditions have been satisfactory since the surgeries.

At the moment, pacemaker implantation is the only treatment for bradycardia that can effectively reduce mortality and improve quality of life. Currently, there are about 1 million patients with bradycardia in China, and about 300,000-400,000 new cases are added each year. However, only about 100,000 patients receive pacemaker installation every year. As the average life expectancy of human beings increases, the aging of the population accelerates, and pacemaker installation becomes more accepted, there will be a greater need by senior patients for pacemaker implantation to restore their normal heartbeat.

About MicroPort® Sorin CRM (Shanghai) Co., Ltd. (“MSC”)

MicroPort® Sorin CRM (Shanghai) Co., Ltd. (MSC) is a subsidiary of MicroPort® Scientific Corporation (00853.HK). As a developer and manufacturer of medical devices for the management of cardiac rhythm disorders, MSC continues to provide high-quality cardiac rhythm management products and services to patients not only in China but also around the world. Its Rega series of pacemakers are comparable to internationally advanced products in terms of size, performance, and duration. In the future, MSC plans to understand further the clinical needs of patients and physicians, and to develop more targeted and refined treatment and management solutions to those living with heart diseases.